Epidermal growth factor receptor rs17337023 polymorphism in hypertensive gestational diabetic women: A pilot study.
Case-control
Epidermal growth factor receptor
Gestational diabetes mellitus
Gestational hypertension
Polymorphism
Single nucleotide polymorphism
rs17337023
Journal
World journal of diabetes
ISSN: 1948-9358
Titre abrégé: World J Diabetes
Pays: United States
ID NLM: 101547524
Informations de publication
Date de publication:
15 Jul 2019
15 Jul 2019
Historique:
received:
20
03
2019
revised:
10
06
2019
accepted:
21
06
2019
entrez:
1
8
2019
pubmed:
1
8
2019
medline:
1
8
2019
Statut:
ppublish
Résumé
Women with gestational diabetes mellitus have an increased risk of developing gestational hypertension, which can increase fetal and neonatal morbidity and mortality. In the past decade, single nucleotide polymorphisms in several genes have been identified as risk factors for development of gestational hypertension. The epidermal growth factor receptor activates tyrosine kinase mediated blood vessels contractility; and inflammatory cascades. Abnormalities in these mechanism are known to contribute towards hypertension. It is thus plausible that polymorphisms in the epidermal growth factor receptor gene would be associated with the development of hypertension in women with gestational diabetes. To determine whether the epidermal growth factor receptor rs17337023 SNP is associated with the occurrence of hypertension in gestational diabetic women. This pilot case-control study was conducted at two tertiary care hospitals in Karachi, from January 2017-August 2018. Two hundred and two women at 28 week of gestation with gestational diabetes were recruited and classified into normotensive ( Subjects were age-matched and thus no difference was observed in relation to age of the study subjects ( This pilot study indicates that polymorphisms in rs17337023 may not be involved in the pathophysiology of gestational hypertension in gestational diabetes
Sections du résumé
BACKGROUND
BACKGROUND
Women with gestational diabetes mellitus have an increased risk of developing gestational hypertension, which can increase fetal and neonatal morbidity and mortality. In the past decade, single nucleotide polymorphisms in several genes have been identified as risk factors for development of gestational hypertension. The epidermal growth factor receptor activates tyrosine kinase mediated blood vessels contractility; and inflammatory cascades. Abnormalities in these mechanism are known to contribute towards hypertension. It is thus plausible that polymorphisms in the epidermal growth factor receptor gene would be associated with the development of hypertension in women with gestational diabetes.
AIM
OBJECTIVE
To determine whether the epidermal growth factor receptor rs17337023 SNP is associated with the occurrence of hypertension in gestational diabetic women.
METHODS
METHODS
This pilot case-control study was conducted at two tertiary care hospitals in Karachi, from January 2017-August 2018. Two hundred and two women at 28 week of gestation with gestational diabetes were recruited and classified into normotensive (
RESULTS
RESULTS
Subjects were age-matched and thus no difference was observed in relation to age of the study subjects (
CONCLUSION
CONCLUSIONS
This pilot study indicates that polymorphisms in rs17337023 may not be involved in the pathophysiology of gestational hypertension in gestational diabetes
Identifiants
pubmed: 31363386
doi: 10.4239/wjd.v10.i7.396
pmc: PMC6656705
doi:
Types de publication
Journal Article
Langues
eng
Pagination
396-402Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Références
Nat Genet. 1999 Jun;22(2):139-44
pubmed: 10369254
Diabetes Care. 2003 May;26(5):1380-4
pubmed: 12716792
Circ Res. 2004 Nov 12;95(10):989-97
pubmed: 15486316
Am J Obstet Gynecol. 2004 Nov;191(5):1655-60
pubmed: 15547538
Gene. 2006 Jan 17;366(1):2-16
pubmed: 16377102
Am J Obstet Gynecol. 2006 Apr;194(4):921-31
pubmed: 16580277
Mol Cell Endocrinol. 2007 Oct 15;277(1-2):6-12
pubmed: 17692454
BMC Cancer. 2007 Oct 24;7:199
pubmed: 17956637
Cancer Genet Cytogenet. 2008 Sep;185(2):69-73
pubmed: 18722874
J Obstet Gynaecol Can. 2008 Mar;30(3 Suppl):S1-S2
pubmed: 18817592
Mini Rev Med Chem. 2009 May;9(5):526-38
pubmed: 19456284
Diabetes Care. 2010 Mar;33(3):676-82
pubmed: 20190296
Best Pract Res Clin Obstet Gynaecol. 2011 Aug;25(4):405-17
pubmed: 21429808
Reprod Sci. 2012 May;19(5):547-54
pubmed: 22344734
Endocrine. 2012 Dec;42(3):700-7
pubmed: 22638611
Int J Immunogenet. 2013 Aug;40(4):299-305
pubmed: 23350658
PLoS One. 2013;8(3):e59254
pubmed: 23555641
Gynecol Endocrinol. 2013 Jul;29(7):657-61
pubmed: 23659736
Diabetes Care. 2014 Jan;37 Suppl 1:S81-90
pubmed: 24357215
J Obstet Gynaecol Can. 2014 Jul;36(7):575-576
pubmed: 25184972
J Ayub Med Coll Abbottabad. 2014 Oct-Dec;26(4):518-21
pubmed: 25672178
PLoS One. 2015 Aug 28;10(8):e0136693
pubmed: 26317342
Genet Mol Res. 2015 Nov 26;14(4):15213-23
pubmed: 26634484
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Hypertens Res. 2017 Mar;40(3):213-220
pubmed: 27682655
PLoS One. 2017 Jul 11;12(7):e0180604
pubmed: 28700691
Tex Heart Inst J. 2017 Oct 1;44(5):350-351
pubmed: 29259508
Acta Obstet Gynecol Scand. 1993 May;72(4):269-72
pubmed: 8389513
Obstet Gynecol. 1997 Dec;90(6):869-73
pubmed: 9397092
Ann Oncol. 1997 Dec;8(12):1197-206
pubmed: 9496384
Diabetes Care. 1998 Aug;21 Suppl 2:B161-7
pubmed: 9704245
Am J Obstet Gynecol. 1998 Oct;179(4):1032-7
pubmed: 9790393